Asian Journal of Andrology

INVITED REVIEW
Year
: 2014  |  Volume : 16  |  Issue : 3  |  Page : 348--353

Radium-223 in metastatic castration resistant prostate cancer


Winston Vuong1, Oliver Sartor2, Sumanta K Pal1 
1 Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
2 Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA

Correspondence Address:
Sumanta K Pal
Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA
USA

In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals. However, from 2010 onwards, 5 additional therapies have been approved on the basis of showing a survival benefit in phase III studies. These agents include sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and (most recently) radium-223. Amongst radiopharmaceuticals currently used for advanced prostate cancer (e.g. samarium-153 and strontium-89), radium-223 possesses several unique properties. As an alpha-emitting compound, the agent produces a high-energy output over a short range, facilitating selective destruction of tissue within the bone in the region of osteoblastic lesions while sparing surrounding normal tissue. The current review will outline biological rationale for radium-223 and also provide an overview of preclinical and clinical development of the agent. Rational sequencing of radium-223 and combinations, in the increasingly complex landscape of mCRPC will be discussed, along with factors influencing clinical implementation.


How to cite this article:
Vuong W, Sartor O, Pal SK. Radium-223 in metastatic castration resistant prostate cancer.Asian J Androl 2014;16:348-353


How to cite this URL:
Vuong W, Sartor O, Pal SK. Radium-223 in metastatic castration resistant prostate cancer. Asian J Androl [serial online] 2014 [cited 2021 Sep 25 ];16:348-353
Available from: https://www.ajandrology.com/article.asp?issn=1008-682X;year=2014;volume=16;issue=3;spage=348;epage=353;aulast=Vuong;type=0